Nkure secures pre-Series A funding for IND submission
- ByStartupStory | April 26, 2023
Nkure Therapeutics successfully closes pre-Series A funding round with Endiya Partners, Kotak Investment Advisors, and Featherlite among investors. The Indian company plans to utilize the investment to finalize its manufacturing protocols, complete preclinical studies, and prepare for IND submission. Nkure aims to offer affordable CAR-NK cell therapy to cancer patients in India, and this funding brings the firm one step closer to its goal.
Nkure, headquartered in Bengaluru, was established in 2022 by Dr. Mahendra Rao, former founding director of the Centre for Regenerative Medicine at the NIH, USA. The Indian company has a team of skilled scientists from the Centre for Cellular and Molecular Platforms (CCAMP) and business experts who have co-founded several prominent healthcare start-ups in India. Nkure is dedicated to providing world-class CAR-NK cell therapy to cancer patients in India at an affordable price point.
After a successful first year, Nkure is experiencing rapid growth. The company has developed an NK cell platform at laboratory scale and has partnered with CDMOs in India and the US. Nkure has obtained exclusive licenses for unique CAR and related technologies that enable allogeneic cell therapy, a first in India. Additionally, the Indian company has received grant funding from the Department of Biotechnology, Government of India. Nkure’s innovative approach and strategic partnerships allow it to provide cutting-edge CAR-NK cell therapy to cancer patients in India at an affordable price point.
Nkure’s innovative approach, along with its state-of-the-art research facility (CCAMP) and upcoming patented technologies, shows promising results for cancer patients in India. The company aims to provide affordable solutions for late-stage leukaemias and solid tumours, offering hope to patients previously thought to be untreatable. Nkure’s groundbreaking technology has the potential to disrupt the traditional approach to cancer treatment and revolutionize the field of oncology.
Nkure’s disruptive technology has the potential to revolutionize the current ecosystem for cancer cell therapy. Dr. Ramesh Byrapaneni, representing Endiya Partners on the Nkure Board, believes that the company is uniquely positioned to overcome scalability and pricing challenges in the industry.
Nitin Deshmukh of Kotak Investments sees the innovative CAR-NK cell therapy platform developed by Nkure as a solution for millions of patients suffering from incurable diseases. The Indian company aims to provide affordable access to cutting-edge cancer treatments and establish itself as a benchmark for quality in cell therapies targeting liquid tumours (leukaemia) and solid tumours.
Calling all entrepreneurs, investors and business owners! The wait is finally over. The 2nd edition of Startup Story B2B Connect is back with a bang – and this time, we’re taking it up a notch. With more startups, more investors and bigger opportunities than ever before, this is your chance to connect, collaborate and take your business to the next level. Get ready for an unforgettable networking experience that’s set to change the game. Stay tuned for all the exciting updates! Register Now Here.
Follow Startup Story
Related Posts
